Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations

@article{Burmeister2006MonitoringMR,
  title={Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations},
  author={Thomas Burmeister and Rolf Marschalek and Bjoern Schneider and Claus Meyer and Nicola G{\"o}kbuget and Stefan Schwartz and Dieter Hoelzer and Eckhard Thiel},
  journal={Leukemia},
  year={2006},
  volume={20},
  pages={451-457}
}
An estimated 10% of acute leukemias carry mixed-lineage leukemia (MLL) fusion genes. Approximately 50 different fusion partners of the MLL gene have already been molecularly identified. These leukemias are commonly regarded as high-risk cases and are treated accordingly with intensified therapy regimens, including hematopoietic stem cell transplantation. However, a subset of patients may achieve long-term remissions with conventional therapy. Monitoring minimal residual disease (MRD) is… Expand
PCR for monitoring of minimal residual disease in hematologic malignancy.
TLDR
Genetic alterations are found in acute myelogenous leukemia patients with cytogenetically normal karyotype and can be considered as applicable targets for monitoring of MRD, among the PCR-based markers. Expand
New insights to the MLL recombinome of acute leukemias
TLDR
The genetic network of reciprocal MLL gene fusions deriving from complex rearrangements is described for the first time, and the distribution of MLL breakpoints for clinical subtypes and fused translocation partner genes (TPGs) will be presented, including novel MLL fusion genes. Expand
Genomic DNA of leukemic patients: Target for clinical diagnosis of MLL rearrangements
TLDR
Recent efforts to analyze chromosomal changes that trigger the development of human acute myeloid and lymphoblastic leukemias are summarized and patient‐specific molecular markers were established that turned out to be a very good source for monitoring minimal residual disease. Expand
Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
TLDR
Assessment of MRD has gained a prominent position in many ALL treatment studies as a tool for tailoring therapy and the results of these studies will answer the question of whether MRD-based treatment intervention is associated with improved outcome. Expand
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
TLDR
Three highly specific and sensitive methodologies for minimal residual disease detection are available, namely multiparameter flow cytometric immunophenotyping, real-time quantitative polymerase chain reaction (RQ-PCR) based detection of fusion gene transcripts or breakpoints, and RQ- PCR-based detection of clonal immunoglobulin and T-cell receptor gene rearrangements. Expand
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
TLDR
It is illustrated that haploidentical transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and posttransplant setting. Expand
The MLL recombinome of acute leukemias
TLDR
The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) was determined and several new TPGs were identified and two new MLL rearrangements are now characterized at the molecular level. Expand
CONCISE REVIEW Why and how to quantify minimal residual disease in acute lymphoblastic leukemia
TLDR
Three highly specific and sensitive methodologies for minimal residual disease detection are available, namely multiparameter flow cytometric immunophenotyping, real-time quantitative polymerase chain reaction (RQ-PCR) based detection of fusion gene transcripts or breakpoints, and RQ- PCR-based detection of clonal immunoglobulin and T-cell receptor gene rearrangements. Expand
The MLL recombinome of acute leukemias in 2017
TLDR
This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients. Expand
A MLL-KIAA0284 fusion gene in a patient with secondary acute myeloid leukemia and t(11;14)(q23;q32).
TLDR
The case of a patient who developed secondary acute myeloid leukemia five years after the patient had received adjuvant radiochemotherapy because of breast cancer is described and the KIAA0284 gene is identified as translocation partner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
The MLL recombinome of acute leukemias
TLDR
The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) was determined and several new TPGs were identified and two new MLL rearrangements are now characterized at the molecular level. Expand
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
TLDR
The standardized RT-PCR protocol and primer sets can now be used for molecular classification of acute leukemia at diagnosis and for MRD detection during follow-up to evaluate treatment effectiveness. Expand
Diagnostic tool for the identification of MLL rearrangements including unknown partner genes.
TLDR
This previously undescribed diagnostic tool has been proven successful for analyzing any MLL rearrangement including previously unrecognized partner genes and is useful for minimal residual disease monitoring of MLL associated acute leukemias. Expand
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
TLDR
The interpretation of RQ-PCR MRD data needs standardized criteria and reporting of MRDData needs international uniformity, and several European networks have now been established and common guidelines for data analysis and for reporting ofMRD data are being developed. Expand
Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors.
TLDR
The data suggest that MLL duplications are not implicated in the malignant transformation in AML, or alternatively, that only a few cells will acquire additional oncogenic mutations necessary to establish themalignant phenotype of AML. Expand
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.
  • K. Döhner, K. Tobis, +4 authors H. Döhner
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Within the subgroup of young adult AML patients with normal karyotype, MLL PTD is associated with short remission duration, and Multivariate analysis identified the MLLPTD status as the single prognostic factor for remission duration. Expand
Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies
TLDR
A paired multiplex reverse-transcriptase polymerase chain reaction analysis is developed to facilitate a rapid and accurate detection of the most frequent MLL fusion genes in adult and childhood acute leukemias. Expand
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
TLDR
It is concluded that cytogenetic analysis at diagnosis should be used to guide treatment decisions in adults with acute lymphoblastic leukemia and remained the most important factor for DFS. Expand
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
TLDR
The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials. Expand
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.
TLDR
Stepwise strategies for selection of stable PCR targets for MRD monitoring should enable successful detection of relapse in most (95%) of childhood precursor-B-ALL. Expand
...
1
2
3
...